Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 6:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 566 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Art Therapy Clear all
Completed Phase 2 Interventional Results available

Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma

NCT00267865
View directory record Official record
Conditions
AIDS-Related-Primary Central Nervous System Lymphoma
Interventions
Methotrexate, Rituximab, Leucovorin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)

NCT04223778
View directory record Official record
Conditions
HIV Infection
Interventions
DOR/ISL, ART
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
15
States / cities
Washington D.C., District of Columbia • Ft. Pierce, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 30, 2026, 6:29 AM EDT
Not yet recruiting Not applicable Interventional

Improving the HIV Care Continuum With mHealth Technology

NCT07631104
View directory record Official record
Conditions
HIV - Human Immunodeficiency Virus, HIV Antiretroviral Therapy (ART) Adherence, mHealth Application, mHealth Intervention, Continuum of Care, Youth With HIV
Interventions
MindBodyU Intervention
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
16 Years to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Phase 1 Interventional

Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV

NCT00545558
View directory record Official record
Conditions
Hepatitis C, HIV Infections
Interventions
Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Cincinnati, Ohio • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Sep 30, 2026, 6:29 AM EDT
Completed No phase listed Observational

Incentives to Promote Medication Adherence Among HIV-Infected Youth

NCT02206906
View directory record Official record
Conditions
HIV
Interventions
Incentive intervention model
Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
16 Years to 24 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Phase 3 Interventional Results available

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

NCT01449929
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
dolutegravir 50 mg OAD, darunavir 800mg OAD, ritonavir 100mg OAD
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 30, 2026, 6:29 AM EDT
Not yet recruiting No phase listed Observational

Building Rapid Inpatient Delivery of ART to Generate Engagement in HIV Care

NCT07847567
View directory record Official record
Conditions
HIV Treatment
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Phase 1Phase 2 Interventional

Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

NCT04983030
View directory record Official record
Conditions
HIV, Acquired Immunodeficiency Syndrome, Immunologic Deficiency Syndrome, Acquired, Sexually Transmitted Diseases, Viral, Retroviridae Infections
Interventions
Ad26.Mos4.HIV, MVA-BN-HIV, PGT121, PGDM1400, VRC07-523LS
Biological
Lead sponsor
Boris Juelg, MD PhD
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Orlando, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Phase 2 Interventional Results available

Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis

NCT01969409
View directory record Official record
Conditions
Ambulatory IPF
Interventions
Rituximab, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 Years

NCT00006509
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452), gp160 MN/LAI-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Sep 30, 2026, 6:29 AM EDT
Not listed Phase 1 Interventional

A Study of Tucaresol in HIV-Infected Patients Who Are Taking Other Anti-HIV Drugs

NCT00006209
View directory record Official record
Conditions
HIV Infections
Interventions
Tucaresol
Drug
Lead sponsor
Aaron Diamond AIDS Research Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Sep 30, 2026, 6:29 AM EDT
Completed No phase listed Observational

Discontinuation of Antiretroviral Therapy in Patients With Asymptomatic HIV Infection

NCT00050284
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
34
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2010 · Synced Sep 30, 2026, 6:29 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV

NCT07053384
View directory record Official record
Conditions
HIV Infections
Interventions
VH3810109, Fostemsavir (FTR), SOC INSTI-based ART
Biological · Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Bakersfield, California • San Diego, California • Ft. Pierce, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Not applicable Interventional Results available

Depression Intervention Among Gay and Bisexual Men Receiving Treatment for Methamphetamine Use

NCT03864653
View directory record Official record
Conditions
HIV/AIDS, Methamphetamine Abuse, Depression
Interventions
MoodGym
Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Sep 30, 2026, 6:29 AM EDT
Recruiting Phase 3 Interventional

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

NCT07682961
View directory record Official record
Conditions
HIV Infections
Interventions
Lenacapavir, Lenacapavir Tablet, Teropavimab, Zinlirvimab, Cabotegravir, Rilpivirine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
16
States / cities
San Francisco, California • DeLand, Florida • Fort Lauderdale, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Not applicable Interventional

Managed Problem Solving to Increase Treatment Adherence in Individuals With HIV

NCT00130273
View directory record Official record
Conditions
HIV Infections
Interventions
Managed problem solving, Standard care
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 13, 2012 · Synced Sep 30, 2026, 6:29 AM EDT
Completed No phase listed Observational

Bone Mineral Density in HIV+ Patients

NCT01378494
View directory record Official record
Conditions
Osteoporosis
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Sep 30, 2026, 6:29 AM EDT
Recruiting No phase listed Observational

Transitional Housing and HIV Health

NCT06829394
View directory record Official record
Conditions
HIV, HIV Antiretroviral Therapy (ART) Adherence, Housing Instability
Interventions
Program Assignment
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 30, 2026, 6:29 AM EDT
Not listed Phase 3 Interventional

Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

NCT00005002
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, HIV-1 Immunogen, Nelfinavir mesylate
Drug · Biological
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
13 Years and older
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Phase 4 Interventional Results available

A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment

NCT00145795
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra + Current Dual NRTI Backbone, Current Regimen
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection

NCT00002347
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir, Nevirapine, Zidovudine, Zalcitabine
Drug
Lead sponsor
Parexel
Industry
Eligibility
13 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Phase 1 Interventional

Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure

NCT03758625
View directory record Official record
Conditions
HIV Infections
Interventions
a1DC + inactivated whole autologous HIV, a1DC + conserved HIV peptides, a1DC + no antigen, pgDC + inactivated whole autologous HIV, pgDC + conserved HIV peptides, pgDC + no antigen
Biological
Lead sponsor
Sharon Riddler
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Phase 1 Interventional Results available

A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy

NCT05261191
View directory record Official record
Conditions
Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1
Interventions
MGD020, MGD014
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
New York, New York • Chapel Hill, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Sep 30, 2026, 6:29 AM EDT
Completed Phase 2 Interventional Results available

Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy

NCT00851786
View directory record Official record
Conditions
Herpes Zoster, HIV Infections
Interventions
ZOSTAVAX, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
43
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 30, 2026, 6:29 AM EDT